BE497282A - - Google Patents
Info
- Publication number
- BE497282A BE497282A BE497282DA BE497282A BE 497282 A BE497282 A BE 497282A BE 497282D A BE497282D A BE 497282DA BE 497282 A BE497282 A BE 497282A
- Authority
- BE
- Belgium
- Prior art keywords
- solutions
- solution
- blood
- serum
- saline
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004833 fish glue Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
<Desc/Clms Page number 1>
PROCEDE POUR LA FABRICATION DE SOLUTIONS DE REMPLACEMENT DU SANG, DE LIQUIDE
SANGUIN, DU PLASMA ET DE SERUM.
L'invention concerne des agents (solutions) de remplacement du sang, de liquide sanguin, du plasma et de sérum. On,utilise jusqu'à pré- sent à cette fin des solutions salines comme par exemple des solutions physiologiques de sel de cuisine, la solution de Ringer, la solution à base de thyrode, la solution de Locke, la solution de la date de Ringer ainsi que des solutions de fumarate ou de succimate des métaux alcalins ou alcalino-terreuxo Ces solutions présentent cependant le désavantage de quitter l'appareil circulatoire en totalité ou en partie, une heure ou deux déjà après l'infusion.
On utilise en outre des solutions colloïdales comme les solu- tions salines de gomme, les solutions de gélatine, de pectine, d'alcool po- lyvinylique de colle de poisson, de méthyl-éther cellulosique, des solu- tions d'alcool de sucre synthétique selon Burgett, des solutions de poly- vinylpyrolidone, des solutions de dextrame de tylose et d'amidon ainsi que de leurs dérivés ou de leurs produits de dégradation et enfin des solutions de glycogène qui contiennent outre le colloïde une quantité correspondante d'une ou de plusieurs sels afin d'atteindre l'isotonie ou l'iso-ionie et la concentration en ions hydrogène qui existent dans le sang complet.
Ces solutions ont le désavantage de s'accumuler plus ou moins dans le RoEoSo, d'y provoquer des transformations et d'être encore décelables dans l'organisme après une longue période. On utilise en ou- tre des solutions de sucre comme les solutions de glucose dans l'eau dis- tillée ou bidistillée, des mélanges de solutions de sucre et de solutions salines telles qu'elles sont décrites ci-dessus, ainsi que des mélanges de glucose ou de sucres spéciaux et d'un sérum salin.
Ce ne sont cepen- dant pas des solutions physiologiqueso Elles saturent plus ou moins for- tement les corps de sucre, et imposent ainsi aux corps déjà parfois ano- xémiques des combustions supplément'aires,
Il reste à considérer enfin les solutions obtenues au moyen de sang animal, comme le plasma dénaturé de veau ou des solutions de sérum
<Desc/Clms Page number 2>
animal qu'on débarasse de leurs antigènes jusqu'à pouvoir les utiliser.
Cependant ces solutions font apparaître parfois des réactions désagré- ables (frissons, accès de fièvre ou augmentation de la fièvre, vomisse- ments, etc...)
Sur la base de ces expériences et de ces observations, on a cherché une solution qui soit tout à fait conforme au point de vue phy- siologique, qui contienne comme substance active une combinaison chi- mique reconnue parfaitement inoffensive et demeure dans l'appareil cir- culatoire de l'homme longtemps encore après l'infusion.
On a trouvé que le choix de l'agent approprié dépend de son action obtu- rante sur les vaisseaux. C'est le cas avec les flavones et leurs dérivés.
Cependant, la rutine (glycoxyde cristallin.de la quercétine) qui est un composé appartenant également, au groupe des flavones, s'est révélé uti- lisable de façon particulièrement avantageuse pour le présent objet.
Par suite de l'action obturante de la rutine, il est acquis de façon certaine que lorsqu'on emploie une solution saline de sérum en mélange avec une quantité contrôlée de cette substance, le liquide infu- sé reste dans l'appareil circulatoire de l'homme aussi longtemps que le résultat à atteindre l'exigée La durée de séjour de telle Solution peut - être fixée en y introduisant différentes concentrations de rutine. Les concentrations de 1 mg. à 1000 mg. par litre de rutine se sont révélées convenables.
Pour réaliser l'invention, on a par exemple procédé de la façon suivante :
On a dissous séparément une quantité exactement pesée du sérum salin dans un volume déterminé d'eau bidistillée.
Après addition de la quantité correspondante de rutine, on mis celle-ci en solution en faisant passer un puissant jet d'air comprimé. Finalement; on à filtré la solution sous pression et on en a rempli des ampoules en verre sans alcali de couleur brun foncé. On a stérilisé les ampoules fermées par fusion.
REVENDICATIONS.-
1.- Procédé pour la fabrication de solutions de remplacement du sang ou de liquide sanguin et de plasma ou de sérum, caractérisé en ce qu'on ajoute à ces solutions des substances'qui obturent les vaisseaux.
20- Procédé pour la fabrication de solutions suivant la reven- dication 1 caractérisé en ce qu'on utilise comme substance d'addition des 'flavones ou leurs dérivés.
**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.
<Desc / Clms Page number 1>
PROCESS FOR THE MANUFACTURE OF BLOOD REPLACEMENT SOLUTIONS, LIQUID
BLOOD, PLASMA AND SERUM.
The invention relates to replacement agents (solutions) for blood, blood fluid, plasma and serum. Saline solutions such as, for example, physiological kitchen salt solutions, Ringer's solution, thyrode-based solution, Locke's solution, Ringer's date solution, have been used for this purpose. as well as solutions of fumarate or succimate of alkali or alkaline earth metals. These solutions, however, have the disadvantage of leaving the circulatory system in whole or in part, an hour or two already after the infusion.
Colloidal solutions such as gum saline solutions, gelatin solutions, pectin, polyvinyl alcohol, fish glue, methyl cellulosic ether, sugar alcohol solutions are also used. synthetic according to Burgett, solutions of polyvinylpyrolidone, solutions of dextrame of tylose and starch as well as their derivatives or their degradation products and finally glycogen solutions which contain in addition to the colloid a corresponding quantity of one or more of several salts in order to achieve isotonicity or isoiony and the concentration of hydrogen ions which exist in whole blood.
These solutions have the disadvantage of accumulating more or less in RoEoSo, of causing transformations there and of still being detectable in the organism after a long period. In addition, sugar solutions such as glucose solutions in distilled or bidistilled water, mixtures of sugar solutions and saline solutions as described above are used, as well as mixtures of sugar. glucose or special sugars and a saline serum.
They are not, however, physiological solutions. They saturate bodies to a greater or lesser extent with sugar, and thus impose additional combustions on bodies which are already sometimes anoxemic.
Finally, it remains to consider the solutions obtained using animal blood, such as denatured calf plasma or serum solutions.
<Desc / Clms Page number 2>
animal that gets rid of their antigens until they can be used.
However, these solutions sometimes show unpleasant reactions (chills, bout of fever or increase in fever, vomiting, etc.)
On the basis of these experiments and observations, a solution has been sought which is completely in conformity with the physiological point of view, which contains as active substance a chemical combination recognized as perfectly harmless and remains in the circulatory system. - human culinary long after the infusion.
The choice of the appropriate agent has been found to depend on its sealing action on the vessels. This is the case with flavones and their derivatives.
However, rutin (crystalline glycoxide of quercetin) which is a compound also belonging to the group of flavones has been found to be particularly advantageous for the present object.
As a result of the sealing action of rutin, it is certain that when a saline solution of serum is used in admixture with a controlled quantity of this substance, the infused liquid remains in the circulatory system of the man as long as the required result to be achieved. The length of stay of such a solution can be fixed by introducing different concentrations of rutin. Concentrations of 1 mg. at 1000 mg. per liter of rutin have been found to be suitable.
To carry out the invention, the following procedure was carried out, for example:
An accurately weighed amount of the saline was dissolved separately in a determined volume of double-distilled water.
After addition of the corresponding amount of rutin, the latter is dissolved by passing a powerful jet of compressed air. Finally; The solution was filtered under pressure and filled into dark brown alkali-free glass ampoules. The sealed ampoules were sterilized by fusion.
CLAIMS.-
1.- Process for the manufacture of solutions for replacing blood or blood fluid and plasma or serum, characterized in that these solutions are added substances which block the vessels.
20. Process for the manufacture of solutions according to claim 1, characterized in that flavones or their derivatives are used as addition substance.
** ATTENTION ** end of DESC field can contain start of CLMS **.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE497282A true BE497282A (en) |
Family
ID=140287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE497282D BE497282A (en) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE497282A (en) |
-
0
- BE BE497282D patent/BE497282A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (en) | Pharmaceutical compositions containing a derivative of 3-hydroxy-butanoic acid chosen among oligomers of this acid and among esters of this acid or of these oligomers with 1,3-butane-diol | |
| FR2625073A1 (en) | INFUSION FLUID FOR ORGAN CONSERVATION | |
| Marion et al. | Efficiency of different concentrations of sodium hypochlorite during endodontic treatment. Literature review. | |
| US1943467A (en) | Pharmaceutical preparation | |
| CN104622896A (en) | Method for preparing sodium-potassium-magnesium-calcium glucose injection | |
| CN103636674A (en) | Peracetic acid disinfectant and preparation method thereof | |
| DK155073B (en) | SOCIAL DISINFECTANT | |
| JP4766653B2 (en) | Ophthalmic pharmaceutical composition | |
| CN103494187A (en) | Preparation method of tartary buckwheat vinegar egg juice | |
| Abbott et al. | Metabolic Alterations Following Thermal Burns: V. The use of Whole Blood and an Electrolyte Solution in the Treatment of Burned Patients | |
| NO129687B (en) | ||
| CN107372604A (en) | A kind of seed disinfectant | |
| FR2491950A1 (en) | INSTANTLY PREPARED CULTURE MEDIUM FOR MICROBIOLOGY AND BACTERIOLOGY AND STERILIZATION METHOD THEREOF | |
| Chang et al. | Nutritional requirements of the common housefly, Musca domestica vicina Macq | |
| Craig et al. | Sodium hypochlorite as an ovicide for Echinococcus | |
| BE520741A (en) | ||
| CN115919669B (en) | Low-ethanol compound hand-washing-free disinfectant suitable for low temperature and preparation method thereof | |
| LAMSON | On the Pharmacological Action of Helenin, the Active Principle of Helenium Autumnale | |
| Jefferson et al. | Efficiency of different concentrations of sodium hypochlorite during endodontic treatment | |
| JP3643879B2 (en) | Electrolyte infusion composition | |
| RU2332994C1 (en) | Method for obtaining stable calcium gluconat solution for injections | |
| US2667440A (en) | Stabilized aqueous solutions of paraminosalicylic acid salts | |
| Dancer | The Medical Assistant | |
| FR2613228A1 (en) | Glucose-based rehydrating composition which is useful, in particular, in the treatment of diarrhoeal states and shock states in calves | |
| FR2696935A1 (en) | New plasma substitute. |